SilverCrest Metals
SILV
Hutchmed (China)
HCM
Cars.com
CARS
Collegium Pharmaceutical
COLL
Halozyme Therapeutics
HALO
US Stock MarketDetailed Quotes
CGEM Cullinan Therapeutics
- 12.820
- +0.550+4.48%
Trading Dec 26 14:30 ET
746.48MMarket Cap-4.51P/E (TTM)
12.830High11.875Low341.43KVolume12.070Open12.270Pre Close4.20MTurnover0.89%Turnover RatioLossP/E (Static)58.23MShares30.18952wk High1.19P/B494.08MFloat Cap10.00052wk Low--Dividend TTM38.54MShs Float59.850Historical High--Div YieldTTM7.78%Amplitude7.300Historical Low12.287Avg Price1Lot Size
About Cullinan Therapeutics Company
Cullinan Therapeutics, Inc. is a biopharmaceutical company engaged in developing oncology and immuno-oncology therapies. The company was founded by Patrick R. Baeuerle on September 15, 2016 and is headquartered in Cambridge, MA.
Company Profile
SymbolCGEM
Company NameCullinan Therapeutics
Listing DateJan 8, 2021
Issue Price21.00
Founded2016
CEOMr. Nadim Ahmed
MarketNASDAQ
Employees85
Fiscal Year Ends12-31
AddressOne Main Street,Suite 1350
CityCambridge
ProvinceMassachusetts
CountryUnited States of America
Zip Code02142
Phone1-617-410-4650
Company Executives
- Name
- Position
- Salary
- Nadim Ahmed
- Director, President and Chief Executive Officer
- 4.01M
- Dr. Jeffrey Alan Jones, M.D.
- Chief Medical Officer
- 2.42M
- Jacquelyn L. Sumer
- Chief Legal Officer, Chief Compliance Officer and Secretary
- --
- Dr. Jennifer Michaelson, PhD
- Chief Scientific Officer
- --
- Mary Kay Fenton
- Chief Financial Officer and Principal Accounting Officer
- --
- Dr. Corinne Savill, PhD
- Chief Business Officer
- --
- Anthony Rosenberg
- Chairman of the Board
- 284.84K
- David D. Meek
- Director
- --
- Dr. Anne-Marie Martin, PhD
- Independent Director
- 164.45K
- Stephen W. Webster
- Independent Director
- 232.24K
- Dr. David P. Ryan, M.D.
- Independent Director
- 43.75K